GoAI
Get started
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc.

2500.HK

HKSEHealthcareMedical - Specialties

Open in GoAI

Latest quote

HK$0.985

−HK$0.035 · -3.43%

Aug 24, 3:00 PM HKT

2500.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
CN
CEO
Hou-Sen Lim
Listed since
Dec 10, 2019
Employees
560

Market position

Day range

Current HK$0.985

52-week range

Current HK$0.985

Open
HK$1.02
Previous close
HK$1.02
Volume
50.5K
0.05× average
Average volume
1.1M
Average daily volume
Market cap
434.4M HKD
Beta
1.16
Market reference 1
50-day average
HK$1.2182
-19.14% below average
200-day average
HK$2.0153
-51.12% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.91×
P/B (TTM)
0.21×
P/S (TTM)
1.21×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
69.05%
Operating margin
-112.56%
Net margin
-132.89%

Financial health

Debt / equity
0.12×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends113%-23%-158%-294%Gross margin, FY2021: 77.99%Gross margin, FY2022: 77.25%Gross margin, FY2023: 79.21%Gross margin, FY2024: 78.11%Gross margin, FY2025: 69.05%Operating margin, FY2021: -67.00%Operating margin, FY2022: -159.97%Operating margin, FY2023: -120.07%Operating margin, FY2024: -73.61%Operating margin, FY2025: -112.56%Net margin, FY2021: -89.85%Net margin, FY2022: -260.22%Net margin, FY2023: -143.22%Net margin, FY2024: -151.71%Net margin, FY2025: -132.89%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 77.99%. Gross margin FY2022 77.25%. Gross margin FY2023 79.21%. Gross margin FY2024 78.11%. Gross margin FY2025 69.05%. Operating margin FY2021 -67.00%. Operating margin FY2022 -159.97%. Operating margin FY2023 -120.07%. Operating margin FY2024 -73.61%. Operating margin FY2025 -112.56%. Net margin FY2021 -89.85%. Net margin FY2022 -260.22%. Net margin FY2023 -143.22%. Net margin FY2024 -151.71%. Net margin FY2025 -132.89%.

Income trends

Revenue

306.79M HKD-34.84%

Operating income

−345.32M HKD+0.37%

Net income

−407.69M HKD+42.92%
Income trends across reported periods646.28M HKD26.65M HKD−592.98M HKD−1.21B HKDRevenue, FY2021: 415.86M HKDRevenue, FY2022: 406.46M HKDRevenue, FY2023: 491.37M HKDRevenue, FY2024: 470.83M HKDRevenue, FY2025: 306.79M HKDOperating income, FY2021: −278.64M HKDOperating income, FY2022: −650.21M HKDOperating income, FY2023: −589.97M HKDOperating income, FY2024: −346.6M HKDOperating income, FY2025: −345.32M HKDNet income, FY2021: −373.64M HKDNet income, FY2022: −1.06B HKDNet income, FY2023: −703.75M HKDNet income, FY2024: −714.31M HKDNet income, FY2025: −407.69M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 415.86M HKD. Revenue FY2022 406.46M HKD. Revenue FY2023 491.37M HKD. Revenue FY2024 470.83M HKD. Revenue FY2025 306.79M HKD. Operating income FY2021 −278.64M HKD. Operating income FY2022 −650.21M HKD. Operating income FY2023 −589.97M HKD. Operating income FY2024 −346.6M HKD. Operating income FY2025 −345.32M HKD. Net income FY2021 −373.64M HKD. Net income FY2022 −1.06B HKD. Net income FY2023 −703.75M HKD. Net income FY2024 −714.31M HKD. Net income FY2025 −407.69M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue306.79M HKD470.83M HKD491.37M HKD406.46M HKD415.86M HKD
Cost of goods sold94.95M HKD103.09M HKD102.17M HKD92.46M HKD91.52M HKD
Gross profit211.83M HKD367.75M HKD389.21M HKD314M HKD324.34M HKD
Research and development267.4M HKD341.19M HKD524.92M HKD527.45M HKD258.34M HKD
Selling, general, and administrative292.24M HKD391.09M HKD454.26M HKD452.56M HKD344.65M HKD
Operating expenses557.15M HKD714.34M HKD977.75M HKD948.88M HKD596.3M HKD
Interest income5.02M HKD10.35M HKD34.46M HKD34.65M HKD49.48M HKD
Interest expense17.81M HKD16.65M HKD62.72M HKD44.62M HKD1.91M HKD
Depreciation and amortization29.89M HKD111.11M HKD124.79M HKD112.35M HKD51.62M HKD
Operating income−345.32M HKD−346.6M HKD−589.97M HKD−650.21M HKD−278.64M HKD
Net income−407.69M HKD−714.31M HKD−703.75M HKD−1.06B HKD−373.64M HKD

Company facts updated Aug 24, 2026.

2500.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

ETFs holding 2500.HK

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
32.16K
Weight
0.00%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%
Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
4.86K
Weight
—
AUM
27.89B USD
Expense ratio
0.33%
Price / 1D
$94.24+0.75%
State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
797
Weight
0.00%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%
Avantis Emerging Markets Small Cap Equity ETF logoAvantis Emerging Markets Small Cap Equity ETFAVEE
Market value
133.21
Weight
—
AUM
122.3M USD
Expense ratio
0.42%
Price / 1D
$68.1949+0.35%

Continue in GoAI

Research 2500.HK

research.disclaimer